Recreational marijuana becomes legal to buy Saturday in Nevada, but that doesn’t mean anything goes in the place where most people think anything goes.
via Here’s what’s legal — and what’s not — in Nevada as recreational weed sales begin — The Cannabist
March 16, 2017
Prior to the change, NIDA had a page on their website titled Is Marijuana Medicine? The page has now been updated with several changes, including a change in title; it is now referred to as simply Marijuana as Medicine, without the question mark. This is a small change, but an important one.
In addition to a change in title, there were multiple other changes made to the page. Below are the seven biggest changes, pointed out by Westword;
1. No link to WhiteHouse.gov
In the first section, titled “What is medical marijuana?,” the explanation of the term begins the same way it did in the last update: It explains what “medical marijuana” is and also states that the FDA has not approved cannabis for medicinal use. Everything else remains the same until the very end of the section. Because the Trump Administration removed the White House website’s page that explains state laws related to marijuana, that link is now missing from the NIDA’s website.
When he ran for president, Donald Trump indicated that he was in favor of marijuana being used for medicinal purposes, but since he took office, his administration has given many signs that that stance has been abandoned, from appointing Jeff Sessions, a staunch anti-marijuana opponent, as attorney general, to multiple statements from press secretary Sean Spicer indicating a potential federal crackdown on cannabis. Just this week, Sessions said marijuana is “only slightly less awful” than heroin.
2. Explaining cannabinoids
In this section, the important change isn’t what’s missing, but what’s been rephrased. In the July 2015 revision, THC was described as “marijuana’s main mind-altering ingredient.” The latest revision adds the words “that makes people, ‘high’.” There’s also a new link link to a page explaining Synthetic Cannabis.
Synthetic marijuana is used primarily to enhance the high in THC-centric marijuana products. Adding information about synthetic marijuana to a section about cannabinoids makes a distinction between natural cannabinoids derived from the plant and synthetic products made in a lab. Most medical products come directly from the plant; this point is important. Multiple studies have shown synthetic marijuana to be more harmful than products made exclusively from the cannabis plant, and THC products get a bad rap when synthetic marijuana causes harmful effects.
3. CBD and childhood epilepsy
One of the most drastic changes is an informational box once titled “What is CBD?” The updated title reads: “CBD and Childhood Epilepsy.”
The box itself explains how CBD can treat epilepsy; the small shift in the headline reflects how accepted this practice has become. So does a change in the verbiage. Instead of reading, “These drugs may be less desirable to recreational users because they are not intoxicating,” the updated version is more direct: “These drugs aren’t popular for recreational use because they aren’t intoxicating.”
This change is major for medical patients: So much of the time, their medicine is compared to THC and negative cultural norms associated with smoking marijuana. Specifying that drugs that medical patients use are not in any way comparable to the high users get from THC is an important distinction.
4. Alzheimer’s disease removed
Alzheimer’s disease was removed from a list of conditions that are the focus of current scientific pre-clinical and clinical trials. That could be because multiple studies have been published since 2015 linking cannabis to improved memory.
Last summer, the Salk Institute discovered a compound in marijuana that helps remove deadly plaque from nerve cells and could be used treat Alzheimer’s. There’s even a medical dispensary in New York that’s partnering with a retirement home to use cannabis to aid in elderly patient care.
5. “State approved”
Four more states legalized medicinal cannabis since the last edit of this page; four more legalized recreational use. In over half of the states in this country, cannabis is legal in some form. The section about potential health risks used to read “regular medicinal use of marijuana is a fairly new practice.” The revision? “State-approved medicinal use of marijuana is a fairly new practice.”
States with legalized marijuana face uncertainty in the age of Trump. But acknowledging that states have approved marijuana for medical use on a government site is significant as the industry grapples with questions about states’ rights.
6. Section on pregnancy
An entire section has been added to the revised page, focusing on the use of medical marijuana during and after pregnancy. The gist: There needs to be more research before a definitive answer can be made about the effects of marijuana on a fetus or infant.
The only study that measures THC in breast milk, for example, is from 1982 and provides data from just two subjects. “All of Colorado policy around marijuana use and breastfeeding is derived from one person’s data,” notes Dr. Heather Thompson, deputy director of Elephant Circle, a local organization working with a physician in Texas who is conducting a study on the effect of THC in breast milk.
7. Medications with cannabinoids
In the section that explains the two FDA-approved drugs containing THC, dronabinol and nabilone, an important sentence was added: “Continued research might lead to more medications.”
Cannabis research had been virtually halted; the federal government prohibits most labs from using any marijuana in studies that isn’t grown from one specific lab. But this is changing. Last summer, the DEA ended the government’s monopoly on cannabis research, which has allowed new groups to study the plant. Then, last winter, the Colorado Department of Public Health put $2.35 million dollars toward funding for seven studies that will hopefully answer some questions about the health and safety impacts of marijuana.
Less than two years after the Drug Enforcement Administration officially admitted that “heroin is clearly more dangerous than marijuana,” new Attorney General Jeff Sessions revisited that comparison in remarks today before law enforcement officials in Richmond:
I reject the idea that America will be a better place if marijuana is sold in every corner store. And I am astonished to hear people suggest that we can solve our heroin crisis by legalizing marijuana — so people can trade one life-wrecking dependency for another that’s only slightly less awful. Our nation needs to say clearly once again that using drugs will destroy your life.
Sessions remarks are contradicted by a wealth of medical and policy research.
For starters, researchers and policymakers aren’t suggesting that marijuana legalization will “solve” the heroin crisis. As I noted late last month, there is, however, abundant, peer-reviewed evidence suggesting that legalizing medical marijuana has led to decreases in opioid overdose and mortality rates in a number of states.
Video of Attorney General Jeff Sessions speaking equating Marijuana to Heroin
And my list is already out-of-date: A new report published in the journal Drug and Alcohol Dependence last month found opioid hospitalizations decreased in states that allowed medical marijuana. Furthermore, those states saw no increase in the incidence of marijuana-related hospitalizations.
That speaks to Sessions’s second point: that marijuana dependency is “only slightly less awful” than heroin addiction. Drug dependency of any kind is, indeed, awful. And marijuana dependency is quite real.
But there is a spectrum of “awful”-ness of drug dependency, and evidence and common sense suggest marijuana and heroin are miles apart. For starters, heroin is lethal and kills 13,000 of its users each year. Nobody ODs on marijuana alone.
Second, the federal government’s own research undermines any equivalency between dependency on marijuana and heroin. You can often gauge how bad a given drug addiction is by looking at what happens when a user tries to kick the habit. For heroin, the National Institute on Drug Abuse lists withdrawal symptoms including “muscle and bone pain, sleep problems, diarrhea and vomiting, cold flashes with goose bumps, uncontrollable leg movements severe heroin cravings.”
Finally, researchers have generally ranked marijuana use as far less harmful to individuals and society than heroin use. In a 2010 Lancet report, dozens of researchers and public health experts rated the harm potential of a variety of drugs on a 0 to 100 scale, with 100 being the most harmful. Heroin scored in the mid-50s. Marijuana was rated at a 20.
Sessions’s remarks are “a sort of starting gun for a new war on drugs,” according to Michael Collins of the Drug Policy Alliance, a group working to reform drug laws. “It’s very disappointing that this DOJ and this attorney general are so anti-science and anti-evidence and anti-facts.”
Video on Legal Medicinal Marijuana States
By Natalie Schwartz, Capital News Service
Patient registry begins this month, but concerned residents are worried that bills may push back the rollout date even further
Source: The Cannabist
ANNAPOLIS, Md. — After Carey Tilghman’s 6-year-old daughter, Paisley, suffered from a stroke, doctors drafted a plan to use a round of Botox injections and muscle relaxers to treat her condition.
Searching for an alternative for her daughter, Tilghman found that a transdermal patch filled with cannabis, which has been linked to shielding the brain from stroke damage, could possibly be helpful to her daughter, but she hasn’t been able access the drug in Maryland’s stalled medical cannabis industry.
Maryland has had one of the slowest rollouts of medical marijuana in the country.
The Natalie M. LaPrade Maryland Medical Cannabis Commission, which grants the licenses to growers, processors and dispensers, has been hampered by legal battles and pending legislation in the Maryland General Assembly since the state legalized medical cannabis in 2014.
This legislative session, state lawmakers are considering a spate of bills outlining different solutions intended to address a lack of diversity in licenses, and two lawsuits that have delayed the rollout of Maryland’s nascent medical cannabis industry.
The commission expects medical cannabis to be available to patients this summer, according to Vanessa Lyon, a spokeswoman for the group. Patient registry for the drug begins this month, but concerned residents are worried that bills may push back the rollout date even further.
“We can’t delay access,” Tilghman said. “(Paisley) deserves to have a transdermal patch and play like a kindergartener can play. They want her on muscle relaxers; they want her to have surgery. How do you be a kindergartner on muscle relaxers?”
“You can’t,” she added, choking up.
The commission was tasked with ensuring racial and geographical diversity in their selection process, and on Dec. 9 it announced pre-approvals for 102 businesses to sell medical cannabis, which broke down into 15 growers, 15 processors, and 72 dispensaries.
However, preference for minority business owners may violate the Constitution, said Cheryl A. Brown Whitfield, principal counsel of the Maryland Department of Transportation.
The state would need to conduct a study to evaluate whether discrimination does exist in the medical cannabis industry before it could take race-conscious measures in awarding licenses, said Zenita Hurley, the attorney general’s director of legislative affairs and civil rights. This study could take up to two years.
The commission used Towson University’s Regional Economic Studies Institute to rank the company applicants. RESI used a double-blind system that did not take into account the race of owners, which resulted in the commission failing to award licenses that ensure adequate minority representation, said Delegate Cheryl Glenn, D-Baltimore.
While the commission has listed the rankings of each company, it has not released the scores and the criteria for which they were ranked, said Darrell Carrington, policy director for the medical cannabis division of Greenwill Consulting, a government relations firm.
“We’re all flying blind right now because the commission refuses to release the scores,” Carrington said. “The rankings are meaningless if we don’t have the scores. How do we know how to move forward properly and know if we’re really making corrections to increase diversity and the like, if we don’t know the difference between (the companies) was 5, 10, or 30 (points).”
Maryland includes a black or African-American population of 30.5 percent, a white population of 59.6 percent, and 9.9 percent who identify as another minority, according to data collected by the U.S. Census as of 2015.
The majority of the companies selected for pre-approvals for growing and processing are led by white owners.
Of the 11 companies with pre-approved growing licenses that reported demographic data to the Maryland Medical Cannabis Commission, about 85 percent of the owners are white, about 8 percent are black, and about 7 percent identify as another racial minority. The nine pre-approved processing companies that reported data showed similar numbers, with 73 percent white ownership, about 15 percent black ownership, and about 12 percent other minority ownership.
The companies selected have about 76 percent male ownership and 24 percent female ownership.
Moreover, after complaints surfaced that the commission didn’t fairly include representation in areas of southeastern Maryland, the commission revised their original unanimous decision on the 15 companies slated to receive growing licenses by bumping two higher-scoring applicants and replacing them with two lower-scoring applicants in the underrepresented areas.
GTI, one of the companies originally awarded a coveted pre-approval license, had already picked out a site in Washington County and began developing a plan to produce medical cannabis when they were replaced, said Delegate Brett Wilson, R-Washington. The company has since joined the other business bumped from the list, Maryland Cultivation and Processing LLC, in suing the commission.
The commission has been operating without oversight or transparency, Glenn said. “They can’t answer why they made the decisions they made.”
To address the lack of ownership diversity, the Legislative Black Caucus, which Glenn heads, has proposed two emergency bills that would overhaul the 15-member commission and reinstate it with members who reflect the racial and geographical diversity of the state.
Sarah Hoyt, director of government affairs for the commission, wrote in testimony that this emergency legislation would “substantially delay the availability of medical cannabis to qualifying patients” by as much as two years.
But Glenn said her legislation would not slow the arrival of the medical cannabis industry.
“The commission operated in an arbitrary, opaque and misleading fashion,” said Pete Kadens, CEO and director of GTI, adding that overhauling the “inefficient” commission would actually speed the rollout of the long-awaited industry.
Kadens said he supported the 15 companies who have been pre-approved to start operating immediately.
“Even though we were displaced for the purpose of geographic diversity, even though we scored higher on merit than five of the companies that now have pre-approvals for the state, even though we feel we were wronged, we do not want the patients of the state to be further distressed,” Kadens said.
One of Glenn’s bills would issue five to seven more licenses for both growers and processors. The bill would also give heavier consideration to businesses with majority black ownership.
The second bill would disband the current commission to create a nine-member Natalie M. LaPrade Medical Cannabis Licensing Unit. This new group would award new grower licenses in future years and would have a fund to provide minority- and women-owned medical cannabis businesses with loans.
Wilson has proposed a separate bill that would increase the number of growers from 15 to 17 to reinstate the two geographically bumped companies’ on the list. This could fix what he called a “fairness issue,” adding that it will likely immediately stop any pending litigation, he said.
Wilson said he doesn’t oppose the other bills and that it’s possible a number of the five bills may merge into “one bill that accomplishes everything.”
“We’re not in conflict with other bills,” Wilson said. “We don’t stand against the other proposals in any way.”
Delegate David Vogt, R-Carroll and Frederick, has also proposed a bill that attempts to squash the pending lawsuits, while also increasing minority and women ownership. His solution would accept the commission’s next 10 ranked applicants, which have been selected as alternates should any of the 15 growing businesses that have been pre-approved fall through.
This bill wouldn’t impact how the commission measures any of the businesses that have been tentatively approved, but it would impact any new ones that haven’t been measured by requiring the commission to give extra weight to minority- and women-owned businesses.
Vogt’s bill also proposes to distribute grant money to the businesses’ local communities. The money would be used for infrastructure improvements, increased security and community development. He added that the amount, $250,000 for each area, is a “nominal amount” and that “ultimately, (the state is) going to get that impact money back — 10, 20 times over — with the tax revenue.”
Vogt, like Wilson, noted that he thinks it’s likely to create one bill that combined components from each to address the problems in the long-awaited industry.
However, Glenn said she only supports the bills she is sponsoring.
Brian Bickerton, chairman of Mazey Farms, an alternate growing company ranked twentieth by the commission, said while he supports Vogt’s bill, he’s in favor of any legislation that moves the industry forward. His company has been waiting to officially launch its business for over two years.
“(It’s) been a long and arduous process,” Bickerton said. “There’s been a lot of tears on our end, but we believe in what we do, we believe in this industry, and we believe in the much-needed medicine that needs to get to the patients.”
Mazey Farms is majority minority-owned, Bickerton said, adding that he thinks the best way to address the lawsuits and the diversity issues is to allow the commission’s next 10 alternative businesses to obtain licenses.
Carrington said it’s hard at this point to know which bill will be “the vehicle that will move (the industry) forward.”
However, taking the next 10 growing alternates, as Vogt’s bill proposes, would significantly address the diversity problem without a delay, Carrington said.
“I can’t stand another delay,” Tilghman said, her daughter, Paisley, leaning on her. “If another delay is put in place (Maryland will) lose a lifelong resident.”
March 7, 2017
The study was published in the latest issue of the journal Frontiers in Pharmacology, and published online by the U.S. National Institute of Health.
“The endogenous cannabinoid (endocannabinoid) system regulates a diverse array of physiological processes and unsurprisingly possesses considerable potential targets for the potential treatment of numerous disease states, including two receptors (i.e., CB1 and CB2 receptors) and enzymes regulating their endogenous ligands N-arachidonoylethanolamine (anandamide) and 2-arachidonyl glycerol (2-AG)”, states the study’s abstract.
“Increases in brain levels of endocannabinoids to pathogenic events suggest this system plays a role in compensatory repair mechanisms.”
It continues; “Traumatic brain injury (TBI) pathology remains mostly refractory to currently available drugs, perhaps due to its heterogeneous nature in etiology, clinical presentation, and severity. Here, we review pre-clinical studies assessing the therapeutic potential of cannabinoids and manipulations of the endocannabinoid system to ameliorate TBI pathology.”
Specifically, the study notes, “manipulations of endocannabinoid degradative enzymes, CB1 and CB2 receptors, and their endogenous ligands have shown promise in modulating cellular and molecular hallmarks of TBI pathology such as; cell death, excitotoxicity, neuroinflammation, cerebrovascular breakdown, and cell structure and remodeling.”
TBI-induced behavioral deficits, such as learning and memory, neurological motor impairments, post-traumatic convulsions or seizures, and anxiety “also respond to manipulations of the endocannabinoid system.”
As such, “the endocannabinoid system possesses potential drugable receptor and enzyme targets for the treatment of diverse TBI pathology.”
The study concludes by stating that; “Promising classes of compounds, such as the plant-derived phytocannabinoids, synthetic cannabinoids, and endocannabinoids, as well as their non-cannabinoid receptor targets, such as TRPV1 receptors, represent important areas of basic research and potential therapeutic interest to treat TBI.”
This study certainly isn’t the first to find cannabinoids to be useful for traumatic brain injury.
For example, a 2015 study published in the journal Annals of Clinical and Translational Neurology found that activation of the body’s cannabinoid receptors can rescue learning and memory after a traumatic brain injury.
A 2014 study published by the American Journal of Surgery came to the conclusion that “A positive THC screen is associated with decreased mortality in adult patients sustaining TBI [traumatic brain injury].”
And a 2013 Cerebral Cortex study found evidence that activation of the body’s cannabinoid receptors may lead to neuroprotective benefits which can help heal the brain after a traumatic injury.
Source: Study: Cannabinoids May Help Treat Traumatic Brain Injury
March 06, 2017
Delegate Mike Pushkin (D) filed House Bill 2677, and Senator Richard Ojeda (D) filed Senate Bill 386. Both would legalize medical cannabis, albeit in different manners. HB 2688 has no cosponsors, whereas SB 386 is cosponsored by a bipartisan coalition of nine senators.
HB 2677 would legalize the possession of up to six ounces of cannabis, and the cultivation of up to 12 plants, for those with a qualifying condition who receive a recommendation from a physician. Qualifying conditions include:
(A) Cancer, glaucoma, positive status for human immunodeficiency virus, acquired immune deficiency syndrome, hepatitis C, amyotrophic lateral sclerosis, Crohn’s disease, agitation of Alzheimer’s disease, Parkinson’s disease, post-traumatic stress disorder, depression, anxiety, addiction to opiates or amphetamines or the treatment of these conditions;
(B) A chronic or debilitating disease or medical condition or its treatment that produces one or more of the following: Cachexia or wasting syndrome; severe or chronic pain; severe nausea; seizures; or severe and persistent muscle spasms, including, but not limited to, those characteristic of multiple sclerosis; or
(C) Any other medical condition or its treatment added by the department, as provided in section six of this article.
The proposal would established a system of licensed and regulated cannabis dispensaries, as a means of safe access to the medicine.
SB 386 would also legalize medical cannabis – including license dispensaries – but in a more limited way. Qualifying conditions include:
(A) A chronic or debilitating disease or medical condition that results in a patient being admitted into hospice or receiving palliative care; or
(B) A chronic or debilitating disease or medical condition or the treatment of a chronic or debilitating disease or medical condition that produces:
(i) Cachexia, anorexia, or wasting syndrome;
(ii) Severe or chronic pain that does not find effective relief through standard pain medication;
(iii) Severe nausea;
(iv) Seizures; or
(v) Severe or persistent muscle spasms.
HB 2677 has been assigned to the House Prevention and Treatment of Substance Abuse Committee. SB 386 has been assigned to the Senate Health and Human Resources.
We have a chance to finally rid ourselves of the Federal Prohibition of marijuana. Representatives Tom Garrett (R-VA) and Tulsi Gabbard (D-HI) have introduced bipartisan legislation, HR 1227, to exclude marijuana from the Controlled Substances Act, thus leaving states the authority to regulate the plant how best they see fit. You can read the bill in its entirety here.
The “Ending Marijuana Prohibition Act of 2017” eliminates federal criminal penalties for possessing and growing the plant. This legislation gives states the power and flexibility to establish their own marijuana policies free from federal interference.
Read the entire article at its Source: End Federal Marijuana Prohibition
The Ending Marijuana Prohibition Act of 2017 was filed by Representatives Tom Garrett (R-VA) and Tulsi Gabbard (D-HI). It would remove marijuana from the federal list of controlled substances, which would end its prohibition on the federal level, allowing states to decide what marijuana policies they want to follow.
The proposal is identical to a measure filed in 2015 by Senator Bernie Sanders.
“I have long believed justice that isn’t blind, isn’t justice”, Representative Garett said in press release about the bill’s introduction. “Statistics indicate that minor narcotics crimes disproportionately hurt areas of lower socio-economic status and what I find most troubling is that we continue to keep laws on the books that we do not enforce. Virginia is more than capable of handling its own marijuana policy, as are states such as Colorado or California.”
Garrett continued; “this step allows states to determine appropriate medicinal use and allows for industrial hemp growth, something that will provide a major economic boost to agricultural development in Southside Virginia. In the coming weeks, I anticipate introducing legislation aimed at growing the hemp industry in Virginia, something that is long overdue.”
The post Bipartisan Legislation to End Federal Marijuana Prohibition Filed in U.S. Congress appeared first on TheJointBlog.com.
Don’t tread on weed: A plea to Trump administration to let marijuana legalization proceed. Denver Post editorial: There’s a need to consider the hard-working American people who benefit from legal cannabis Published: Dec 23, 2016, 6:42 am • Updated: about a month ago Comments (12) By The Denver Post Editorial Board Last week came […]
Last week came the news that Colorado’s legal cannabis industry topped $1 billion in sales in the first 10 months of the year. While anyone familiar with the trends expected a breakthrough this year, the industry’s early surpassing of that lofty mile-marker presents plenty of cause for reflection.
We bring it up because next year a new top cop will take the helm under President-elect Donald Trump, and there is some cause for worry should he be confirmed by the Senate.
Trump’s pick for attorney general, Sen. Jeff Sessions, of Alabama, is anti-cannabis. From once joking that he thought members of the Ku Klux Klan were OK until he learned some of them smoked pot, to saying in April that “Good people don’t smoke marijuana,” Sessions believes weed is dangerous and shouldn’t be legal. He is critical of the Obama administration’s relatively hands-off approach toward states whose voters approved the drug.
American legalization’s fate: What’s next for U.S. marijuana industry under President Trump?
Jeff Sessions: Trump’s pick for attorney general not fan of legal weed
Platforms: What you need to know about Trump’s marijuana views
Weed news and interviews: Get podcasts of The Cannabist Show.
Subscribe to our newsletter here.
Watch The Cannabist Show.
Peruse our Cannabist-themed merchandise (T’s, hats, hoodies) at Cannabist Shop.
Should an Attorney General Sessions decide to flout the rights of states that have undertaken the cannabis experiment, and return the agency to aggressive enforcement of federal marijuana laws, he could easily start arresting growers, retailers and users. But would he really want to do that?
We offer some reasons for the future Trump administration to not only maintain the current president’s kindness, but to see the advantages for hard-working American people who benefit from legal pot.
Given Election Day victories for medical and recreational pot in eight states, more than half the states in the U.S. have now approved sales and use of medical marijuana, and 65 million people live in states that green-lighted recreational sales.
Colorado’s current haul helps fuel national estimated sales of $7.4 billion in 2016. Now that California voters have followed our lead, it’s possible that another $6.5 billion could be added to national tallies from the Golden State alone by 2020.
The legal cannabis industry is the fastest-growing sector in Colorado, and it employed more than 18,000 direct and related full-time workers in 2015.
For a president-elect looking to create and keep good jobs in the United States, a crackdown on this burgeoning industry would seem a poor move indeed. It’s just math. To keep several hundred manufacturing jobs in Indiana, Trump had to cajole a major U.S. company and the state had to offer millions of dollars in tax breaks.
Guess what? Colorado’s cannabis industry, as in other states, isn’t outsourcing overseas and makes its money without government subsidies or tax breaks. Meanwhile, the industry is dumping significant tax and sin tax revenue into the state’s coffers.
Colorado’s experience has shown that legal sales of cannabis can be accomplished with plenty of regulatory oversight and without the horror-story outcomes of a strung-out populace. In fact, voters in Denver — the world’s largest legal cannabis market — just said “yes” again to the experiment by giving the thumbs-up to a pilot program that allows businesses to offer pot use to their customers. Clearly no reefer-madness backlash here.
Sessions hasn’t signaled what he would do regarding pot enforcement as attorney general. Perhaps he already sees the benefit. But conservatives should get it in writing, stand up for states’ rights and allow the success of this new industry to continue.
To send a letter to the editor about this article, submit online or check out our guidelines for how to submit by e-mail or mail.
At a press conference today Attorney General Jeff Sessions made new, and disparaging, comments on marijuana. “Most of you probably know I don’t think America is going to be a better place when more people of all ages and particularly young people start smoking pot,” Sessions told reporters today. “I believe it’s an unhealthy practice…
via Attorney General Jeff Sessions Makes New Disparaging Comments on Marijuana — TheJointBlog.com
A Journey of Discovery
Believing in Your Authenticity Isn’t a Luxury, It’s the Wellspring of Your Joy
Don't try to move mountains by yourself. You'll hurt your back. God can help.
Organic Herbs, Herbals, Sustainable Gardening
Thoughts and dreams
Myths and Magic
What has America become is not the question. Why is America still like this?
Aromatherapy and life
A daily selection of the best content published on WordPress, collected for you by humans who love to read.
Body of a Sinner Mind of a Saint
Just another WordPress.com site
Gold is where you find it!!!!
Seeking Ideas Beyond Conventional Thought
Musings by Oro Cas
Exploring the world with Curtis and Peggy Mekemson
Law Office of Aquanetta J. Betts, LLC, District of Columbia and Maryland, www.abettslaw.com, 410.701.0127. Copyright 2017. All Rights Reserved. This blog is for informational purposes only.
Denver, Colorado marijuana news, culture, resources
Musings by Oro Cas
keeping your stash sticky since 2010
Learn, Live and Protect your rights
The Art and Craft of Blogging
The latest news on WordPress.com and the WordPress community.
Oro Cas Reflects 
You must be logged in to post a comment.